Sort   by:  
 Page size 
UnknownManagement of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.
Not available
S-EPMC8666642 | biostudies-literature
UnknownEncorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Not available
S-EPMC8078423 | biostudies-literature
UnknownBinimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.
Not available
S-EPMC7370699 | biostudies-literature
UnknownMILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Not available
S-EPMC7655017 | biostudies-literature
Sort   by:  
 Page size